Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.

Sponsor
Henan Cancer Hospital
Study ID
NCT03163381
Phase
PHASE2
Status
Unknown

Conditions

  • Osteosarcoma, Advanced

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib 500mg,po,qd,medicine to disease progression.

Study Details

Apatinib second line treatment for Advanced osteosarcoma and soft tissue sarcomas ,openting ,single center, one-armed clinical study.

Key Dates

Start date
Apr 11, 2017
Status verified
May 2017
Primary completion
Oct 11, 2017
Completion
Apr 11, 2019

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib
    Apatinib 500mg/d from day 1 to day 28, repeated every 28 days until progressive Disease(PD) .

Primary Outcome Measure

progress free survival [ Time Frame: 6 months ]

Central Contacts